PIM1 and neuroblastoma: For instance, IBL‐302, a PIM/PI3K/mTOR triple kinase inhibitor, was recommended for MYCN-amplified NB treatment (3), whereas Periposine, an Akt inhibitor, was invalid for MYCN-amplified NB (4).